logo
  

Qudian Announces Authorization To Repurchase $300 Mln ADSs

Qudian Inc. (QD) announced Monday that its board has authorized a share repurchase program for up to $300 million worth of its outstanding American depositary shares or ADSs, over the next 36 months starting from June 13, 2024.

Each ADS of the consumer-oriented technology company will represent one Class A ordinary share, and/or Class A ordinary shares.

The repurchase is for a time to time buy through open market at prevailing market prices, privately negotiated transactions, block trades or any combination thereof.

The Company plans to fund the repurchases from its existing cash balance and does not expect to adversely affect its existing business strategies.

In the pre-market session, shares are at $2.55, up 2.55 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings... Target Corp. shares were losing more than 8 percent in pre-market activity on the NYSE after the general merchandise retailer reported weak profit, sales and comparable sales in its first quarter. Earnings per share missed the Street estimates. Further, the company issued second-quarter outlook and maintained fiscal 2024 forecast. Shares of Marks and Spencer Group Plc or M&S were gaining more than 7 percent in the morning trading in London after the retail major reported Wednesday significantly higher profit and sales in its fiscal 2024. The company also announced a dividend, and said it is confident to make further progress in 2025 and beyond.

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT